Esmo Open

In the last decade, we have seen a significant change in the therapeutic landscape for advanced melanoma. Recently, results from two trials evaluating immunotherapy and targeted therapy in the adjuvant setting (completely resected stage III/IV) were published. In this podcast, Teresa Amaral, member of the ESMO YOC, talks with Professor Jeffrey Weber, Professor of Oncology and Deputy Director of the Laura and Isaac Perlmutter Cancer Center, about the recent developments in adjuvant therapies for patients with melanoma. Professor Weber also gives some insight on this data's impact on the treatment of real-world patients. Currently, there is enough evidence to support adjuvant treatment in patients with resected Stage IIIB/C-IV melanoma. As for Stage II patients, this option should be considered in some selected cases (e.g. T ≥ 4mm with the presence of ulceration). In both of the above-mentioned trials, patients were treated for a maximum of 12 months. Although a shorter treatment duration (e.g. 6 months) mig